,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['trastuzumab', 'breast']
pat lorusso, do, will share insights as discussant for the destiny clinical trial of trastuzumab deruxtecan in patients with with her2-low unresectable and/or metastatic #breastcancer. join dr. lorusso &amp; colleagues at 2pmcst today in hall b1 #asco22 
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.